Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

August 4, 2023

Consolidated Financial Results
for the Three Months Ended June 30, 2023
(Under Japanese GAAP)
Company name:
Mochida Pharmaceutical Co., Ltd.
Listing:
Tokyo Stock Exchange
Securities code:
4534
URL:
https://www.mochida.co.jp/english/
Representative:(Name) Naoyuki Mochida (Title) Representative Director, President
Inquiries:(Name) Kenichi Miyamoto (Title) Head of Finance & Accounting Department
Telephone:+81-3-3358-7211
Scheduled date to file quarterly securities report:
August 9, 2023
Scheduled date to commence dividend payments:
Preparation of supplementary material on quarterly financial results: None
Holding of quarterly financial results briefing:
None(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2023 (from April 1, 2023 to June 30,2023)(1) Consolidated operating results (cumulative)
Net sales
Three months ended(Percentages indicate year-on-year changes.)

Operating profit

Profit attributable toowners of parent

Ordinary profit

Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

June 30, 2023

24,747(10.6)

2,515(41.0)

2,592(41.3)

1,688(46.5)

June 30, 2022

27,692

1.2

4,265

34.0

4,415

31.2

3,155

18.9

Note: Total comprehensive income

For the three months ended June 30, 2023:
For the three months ended June 30, 2022:

Basic earnings pershare

Diluted earnings pershare

YenYenThree months ended
June 30, 202346.24-

June 30, 2022

83.98

-

¥2,427 million¥3,288 million[(26.2)%][34.4%](2) Consolidated financial position
Total assets
As ofNet assets

Equity-to-asset ratio

Millions of yen

Millions of yen

June 30, 2023

157,399

127,575

81.1

March 31, 2023

158,831

126,775

79.8

Reference:

EquityAs of June 30, 2023:
As of March 31, 2023:¥127,575 million¥126,775 million%

2. Cash dividends
Annual dividends per shareFirst
quarter-end

Secondquarter-end

Yen
Fiscal year ended-March 31, 2023
Fiscal year ending

Thirdquarter-end

Yen

Fiscal year-end

Yen

Total

Yen

Yen

40.00

-

40.00

80.00

40.00

-

40.00

80.00

-March 31, 2024
Fiscal year ending

March 31, 2024 (Forecast)

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2024 (from April 1, 2023 toMarch 31, 2024)(Percentages indicate year-on-year changes.)
Net sales
Millions ofyen

Operating profit%

Millions ofyen%Millions ofyen

Full year
104,000
0.7
8,500(0.1)
8,700Note: Revisions to the financial result forecast most recently announced: None

*Profit attributable toowners of parent

Ordinary profit

Basic earnings
per share%

Millions ofyen%

Yen(4.2)

6,300(5.3)

172.68Notes(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in change inscope of consolidation): None
(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements:
Yes(3) Changes in accounting policies, changes in accounting estimates, and restatement(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None(iv) Restatement: None(4) Number of issued shares (common shares)(i)

Total number of issued shares at the end of the period (including treasury shares)
As of June 30, 2023

38,500,000 shares

As of March 31, 2023

38,500,000 shares(ii) Number of treasury shares at the end of the period
As of June 30, 2023

2,016,091 shares

As of March 31, 2023

1,967,279 shares(iii) Average number of shares outstanding during the period (cumulative)
Three months ended June 30, 2023

36,511,601 shares

Three months ended June 30, 2022

37,569,520 shares* Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants
or an audit corporation.
* Explanation of the proper use of financial result forecasts and other special matters
The financial result forecasts presented in this document are based on information that is currently available tothe Company as of the announcement of this document, and the Company does not guarantee to achieve them.
In addition, actual financial results may differ significantly from these forecasts due to a wide range of factors.

Quarterly Consolidated Financial Statements(1) Quarterly Consolidated Balance Sheets(Millions of yen)
As of March 31, 2023
AssetsCurrent assets
Cash and deposits
Accounts receivable - trade
Securities
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures, net
Machinery, equipment and vehicles, netLand
Other, net
Total property, plant and equipment
Intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Other
Total investments and other assets
Total non-current assets
Total assets

1

As of June 30, 2023

47,01027,806
13,49914,644
1,453
8,307
4,656
117,379

42,01427,871
13,49917,165
1,644
9,159
4,035
115,390

7,069
1,854
4,990
1,135
15,049
797

6,986
1,751
4,962
1,107
14,807753

14,2463,883
7,476
25,60541,452
158,831

15,652
3,562
7,232
26,44742,008157,399

(Millions of yen)
As of March 31, 2023
Liabilities
Current liabilities
Notes and accounts payable - trade
Electronically recorded obligations - operating
Income taxes payable
Provision for bonuses
Other provisions
Other
Total current liabilities
Non-current liabilities
Retirement benefit liability
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’ equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Total net assets
Total liabilities and net assets

2As of June 30, 2023

9,047
910
501
2,313
169
14,31627,258

9,900
878
699
1,042
112
12,38925,021

4,133
664
4,798
32,056

4,120
681
4,802
29,824

7,229
1,871
118,943(7,114)
120,930

7,229
1,871
119,170(7,280)120,991

5,655
189
5,844
126,775
158,831

6,405
178
6,583
127,575
157,399

(2) Quarterly Consolidated Statements of Income and Comprehensive Income
Quarterly Consolidated Statements of IncomeThree Months Ended June 30(Millions of yen)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Share of loss of entities accounted for using equity
methodCommission expenses
Foreign exchange losses
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Settlement income
Total extraordinary income
Extraordinary losses
Loss on sale and retirement of non-current assets
Total extraordinary losses
Profit before income taxes
Income taxes
ProfitProfit attributable to owners of parent

For the three months ended
June 30, 2022
27,692
12,434
15,257
10,9924,265

For the three months ended
June 30, 2023
24,747
11,542
13,205
10,689
2,515

0
171
29
201

0
181
36
218

―
―

043

3
45
2
51
4,415

3
90
3
142
2,592

―
―

1111

1
1
4,414
1,259
3,155
3,155

31
31
2,572
884
1,688
1,688

3

Quarterly Consolidated Statements of Comprehensive Income
Three Months Ended June 30(Millions of yen)

ProfitOther comprehensive income
Valuation difference on available-for-sale securities
Remeasurements of defined benefit plans, net of tax
Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners of parent

For the three months ended
June 30, 2022
3,155

For the three months ended
June 30, 2023
1,688143(10)133
3,288750
(11)
738
2,427

3,288

2,4274

Sales of Main Products（Three months ended June 30, 2023)（Billions of yen）
Products

Fiscal year ended

Fiscal year ending

March 31, 2023

March 31, 2024

Apr-Jun

Apr-MarApr-JunApr-Mar
forecast

Threemonths
Y o Ychanges%Treatment of ulcerative colitis

Lialda®

3.4

13.5

3.6

14.0+ 5%Treatment for chronic constipation

Goofice®

1.7

6.9

1.9

9.0+ 10%

AntidepressantLexapro®

4.0

11.0

1.3

8.5

△ 68%

Drug for hyperlipidemia andarteriosclerosis obliterans

Epadel

1.9

7.1

2.0

7.4

+ 4%

Treatment for chronic constipation

Movicol®

1.4

5.4

1.4

6.2

△ 2%

Gout and hyperuricemia

Urece®

0.4

2.2

0.7

4.0+ 55%

Calcium channel blocker with a longacting hypotensive effectAnalgesic for chronic pain and pain
after tooth extraction
Treatment for pulmonary arterial
hypertension

Atelec®

0.7

2.6

0.61.9△ 17%

Tramcet®

0.8

2.90.61.8△ 23%

Treprost®

0.4

1.6

0.4

1.8+ 4%

Heparin Sodium
MOCHIDA

0.3

1.2

0.3

1.2+ 1%

Beselna

0.2

1.1

0.2

1.0+ 2%Dinagest

0.9

1.8

0.20.8△ 67%

Generic drugs

7.0

29.5

7.4

30.2

+ 6%

Skin Care Products

1.4

5.9

1.66.3+ 11%

Anticoagulant agent
Therapeutic agent for condyloma
acuminatum and actinic keratosis
Therapeutic agent for endometriosis,adenomyosis and dysmenorrhea

Lexapro® sales of the fiscal year ended march 31, 2023 are the sum of Mochida's own sales and sales to
Mitsubishi Tanabe Pharma Corporation.
Atelec® sales are the sum of Atelec® and Atedio® sales.

5Development Pipeline【Ethical drug】
Development code
<Generic name>
MD-0901<mesalazine>

MND-21<ethyl icosapentate>

ACT-541468<daridorexant>

FYU-981<dotinurad>MD-711<treprostinil>

Indications

Formulation

Phase Ⅲ

Ulcerative colitis（pediatric indication）

OralLicensed-in from Takeda Pharmaceuticals U.S.A., Inc.
In-house development<Japan>

Phase Ⅲ

Hypertriglyceridemia

Oral

Collaboration with Sumitomo Pharma (Suzhou) Co.,
Ltd.<China>

Phase Ⅲ

Insomnia

Oral

Co-development with Idorsia Pharmaceuticals
Japan<Japan>

Phase Ⅲ

Gout andhyperuricemia(pediatric indication)

Oral

Co-development with FUJI YAKUHIN Co., Ltd.<Japan>

Phase Ⅱ / Ⅲ

Pulmonary
hypertension
associated withinterstitial lungdiseaseStageRemarks<Development country>

Licensed-in from United Therapeutics Corporation

Inhalant In-house development<Japan>【Medical device】
Development code
<Generic name>* ｄMD-001<sodium alginate>

ｄMD-002<sodium alginate>StageRemarks<Development country>

Intended use or indications

FiledArticular cartilage lesion

In-house development<Japan>

Therapeuticexploratory study

Cavernous nerve injury

In-house development<Japan>

Stages of Medical devices are classified into “Terapeutic confirmatory study” and “Therapeutic exploratory study”.
＊ Update from May 15, 2023

6